AnthonisenNR, ConnettJE, KileyJP, AltoseMD, BaileyWC, BuistAS, et al. Effects of smoking intervention and the use of inhaled anti-cholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497–1505.
2.
RennardSI, SerbyCW, GhafouriM, JohnsonPA, FriedmanM.Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest1996;110(1):62–70.
3.
RodriguezBL, MasakiM, BurchfielC, CurbJD, FongKO, ChyouPH, MarcusEB. Pulmonary function decline and 17-year total mortality. The Honolulu Heart Program. Am J Epidemiol1994;140(5):398–408.
4.
KannelWB, LewEA, HubertHB, CastelliNP. The value of measuring vital capacity for prognostic purposes. Trans Assoc Life Insur Med Dir Am1980;64:66–83.
5.
HillemanDE, MohiuddinSM, DelcoreMG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine and buspirone in smoking cessation. J Clin Pharmacol1994;34(3):222–224.
6.
HurtRD, SachsDP, GloverED, OxfordKP, JohnstonJA, DaleLC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med1997;337(17):1195–1202.
